FOCUS IP Holding is building a network of Drug Development Centers around the globe. The scaled business plans of these subsidiaries materialize all on the steep increase in value by delivering Proof of Concept stage prototype products for the pharmaceutical industry. Core to the operative part of FOCUS IP is an established scouting team for new interesting molecules gathered from academia, biotech and pharma companies funneled into an intellectual property database and due diligence portfolio. Each Center will in-licence biologically active molecules at discovery stage and develop a pipeline of innovative and proprietary drugs, with constant output of licence opportunities for pharma company new product pipelines.

Originators and discovery companies are encouraged to contact us and benefit from our clinical Proof of Concept expertise as well as our financial development model for joint value creation before licensing at PoC.FOCUS IP (located in Neuss, Germany and Basel, Switzerland) represents the operative part which has built already a perfect supply and drug development chain for the individual Drug Development Centers.The scouting and due dilligence activities of FOCUS IP are also offered to other companies to support their pipeline needs. The service includes strategic and regulatory development paths, planning for optimum value creation, project valuation, de-risking strategies, preperation of licensing packages.